Principal Financial Group Inc. Has $194.25 Million Stock Position in Stryker Corporation $SYK

Key Points

• Principal Financial Group boosted its stake in Stryker by 46.9% to 552,672 shares (worth about $194.25 million), representing roughly 0.14% ownership at the end of the quarter.
• Stryker missed quarterly estimates, reporting $2.60 EPS vs. $2.98 expected and $6.02B revenue vs. $6.34B expected (revenue up 2.6% YoY), and issued FY2026 EPS guidance of 14.900–15.100.
• The stock has a market cap of about $113.1B and a PE of 34.19, with institutional investors owning 77.09% and analysts assigning a consensus rating of "Moderate Buy" with a $395.48 target.

Principal Financial Group Inc. lifted its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 46.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 552,672 shares of the medical technology company's stock after purchasing an additional 176,363 shares during the period. Principal Financial Group Inc. owned 0.14% of Stryker worth $194,248,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in SYK. Venturi Wealth Management LLC increased its holdings in Stryker by 1.4% during the third quarter. Venturi Wealth Management LLC now owns 1,904 shares of the medical technology company's stock worth $704,000 after buying an additional 27 shares during the last quarter. Wolff Wiese Magana LLC lifted its stake in Stryker by 2.3% in the third quarter. Wolff Wiese Magana LLC now owns 1,271 shares of the medical technology company's stock valued at $470,000 after acquiring an additional 28 shares during the last quarter. Lantz Financial LLC grew its position in shares of Stryker by 5.0% in the 3rd quarter. Lantz Financial LLC now owns 608 shares of the medical technology company's stock valued at $225,000 after acquiring an additional 29 shares during the period. Stonebridge Capital Advisors LLC increased its stake in shares of Stryker by 0.4% during the 3rd quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company's stock worth $2,661,000 after purchasing an additional 29 shares during the last quarter. Finally, Tcfg Wealth Management LLC increased its stake in shares of Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company's stock worth $403,000 after purchasing an additional 29 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Trading Up 1.5%

Shares of Stryker stock opened at $295.39 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The firm has a 50-day moving average of $343.97 and a 200-day moving average of $356.28. Stryker Corporation has a 52-week low of $290.17 and a 52-week high of $404.87. The stock has a market cap of $113.13 billion, a PE ratio of 34.19, a PEG ratio of 1.72 and a beta of 0.80.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the prior year, the business posted $2.84 earnings per share. Stryker's revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.

Analyst Upgrades and Downgrades

SYK has been the subject of several recent analyst reports. BTIG Research cut their target price on shares of Stryker from $397.00 to $379.00 and set a "buy" rating for the company in a research note on Friday, May 1st. Evercore set a $355.00 price target on Stryker in a research report on Friday. Raymond James Financial upgraded Stryker from a "market perform" rating to an "outperform" rating and set a $418.00 price objective on the stock in a research note on Tuesday, January 6th. Robert W. Baird set a $385.00 price objective on Stryker in a research report on Friday. Finally, Leerink Partners assumed coverage on Stryker in a report on Monday, April 13th. They set an "outperform" rating and a $410.00 target price on the stock. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.